

SOCIAL VALUE POLICY

TABLE OF CONTENTS

Topic	Clause(s)
Scope and Applicability	Clause 1.1 – 1.3
Definitions	Clause 2.1 – 2.3
Legislative and Policy Framework	Clause 3.1 – 3.3
NHS and Social Value	Clause 4.1 – 4.3
Weighting and Qualitative Assessment	Clause 5.1 – 5.3
Measurement and Reporting	Clause 6.1 – 6.3
Sector-Specific Guidance for CGM Manufacturers	Clause 7.1 – 7.4
Sector-Specific Guidance for Wheelchair Manufacturers	Clause 8.1 – 8.5
Supply Chain and Ethical Considerations	Clause 9.1 – 9.3
External Programmes and Alliances	Clause 10.1 – 10.3
Monitoring and Review	Clause 11.1 – 11.2
Training and Awareness	Clause 12.1 – 12.3
Digital Inclusion and Data Ethics	Clause 13.1 – 13.3
Social Innovation and Co-Production	Clause 14.1 – 14.3

Clause 1: Scope and Applicability

1.1 This Social Value Policy (“the Policy”) sets out Urathon Ltd’s (“the Company”) legal and strategic approach to delivering demonstrable social value through all business activities, particularly those relating to UK public sector procurement, including NHS, local government, and devolved administrations.

1.2 The Policy is binding on all directors, officers, employees, contractors, suppliers, and joint venture partners, and forms part of the Company’s broader ethical governance framework, including its Code of Conduct and Modern Slavery Statement.

1.3 This Policy supports Urathon’s core mission to improve lives through inclusive innovation, responsible medical technology, and sustainable healthcare partnerships, and is fully aligned with the **Public Services (Social Value) Act 2012**, **Procurement Act 2023**, and the **NHS England Social Value Model**.

Clause 2: Definitions

2.1 **Social Value** means the wider benefit to society resulting from the Company’s actions, including but not limited to improvements in health equity, environmental outcomes, economic opportunity, and community resilience.

2.2 **Weighting** refers to the legally mandated allocation of scoring in public tenders under the **Procurement Act 2023**, whereby social value must be assessed and constitute a minimum 10% of award criteria.

2.3 **Qualitative Assessment** means the evidence-based evaluation of a supplier’s proposed social value commitments using models such as the **Model Evaluation Framework** or **National TOMs (Themes, Outcomes, Measures)**.

Clause 3: Legislative and Policy Framework

3.1 The Company shall ensure all bids and commercial activities comply with:

- **Procurement Act 2023**
- **Public Services (Social Value) Act 2012**
- **Health and Social Care Act 2012**

- **Equality Act 2010**
- **NHS Social Value Model (2021)**

3.2 All social value activity must support at least one of the five core UK government social value themes:

- COVID-19 recovery
- Tackling economic inequality,
- Fighting climate change,
- Equal opportunity, and
- Improving health and wellbeing.

3.3 In devolved contexts, the Company shall comply with the **Well-being of Future Generations (Wales) Act 2015** and equivalent social partnership legislation.

Clause 4: NHS and Social Value

4.1 In NHS procurement, the Company shall articulate specific social value outcomes related to population health, care access, and reducing health inequalities.

4.2 Tender responses shall be aligned with **NHS England's Social Value Model, ICS (Integrated Care System)** strategies, and local Joint Strategic Needs Assessments (JSNAs).

4.3 Patient-centric outcomes, digital equity, and health literacy for marginalised groups shall be prioritised.

Clause 5: Weighting and Qualitative Assessment

5.1 All relevant NHS and public sector bids shall include a minimum 10% social value weighting, and where directed, up to 20% in line with contracting authority policy.

5.2 Social value proposals must be substantiated with evidence, realistic delivery plans, and KPIs using frameworks such as the **Model Evaluation Framework** and **Social Value Portal's TOMs**.

5.3 Commitments shall be contractually binding, with breach remedies and performance tracking incorporated into contract management.

Clause 6: Measurement and Reporting

6.1 Social value performance shall be monitored via quarterly KPI reports, published annually in Urathon's ESG report.

6.2 Tools such as the **NHS Outcomes Framework**, **Social Return on Investment (SROI)**, and third-party audits may be used to evaluate delivery.

6.3 Data transparency and assurance standards shall be applied consistently across all sectors and geographies.

Clause 7: CGM Sector-Specific Guidance

7.1 In its Continuous Glucose Monitoring (CGM) operations, the Company shall deliver outcomes including health literacy, access to digital diabetes care, and early intervention support.

7.2 Emphasis shall be placed on addressing disparities in diabetes prevalence and control among underrepresented or socioeconomically disadvantaged populations.

7.3 All CGM suppliers must comply with **NHS procurement standards**, **MHRA regulations**, and demonstrate alignment with NICE recommendations.

7.4 Community education, job creation, and partnerships with primary care networks shall form part of the social value strategy.

Clause 8: Wheelchair Sector-Specific Guidance

8.1 As a supplier of mobility equipment, the Company shall prioritise user dignity, independence, and access to customised mobility solutions.

8.2 Bid proposals shall demonstrate how products reduce physical, social, and psychological barriers to independence.

8.3 Collaboration with the **Wheelchair Alliance**, **AT2030 Programme**, and user-led design panels is encouraged.

8.4 Social value will include accessibility improvements in built environments, especially for

home and care settings.

8.5 All claims will be supported by case studies, clinical data, and service-user feedback.

Clause 9: Supply Chain and Ethical Considerations

9.1 Tier 1 and Tier 2 suppliers must comply with the **Modern Slavery Act 2015**, **UK Bribery Act 2010**, and **Environmental Protection Act 1990**.

9.2 Ethical procurement shall include due diligence, fair working conditions, local supplier engagement, and carbon impact reduction.

9.3 Supply chain mapping, worker rights verification, and subcontractor monitoring shall be embedded into all procurement activities.

Clause 10: External Programmes and Alliances

10.1 The Company will actively partner with VCSEs (Voluntary, Community and Social Enterprises), particularly those supporting disadvantaged groups or health equity.

10.2 Participation in social innovation schemes, such as **NIHR partnerships**, **Wheelchair Alliance**, or **AT2030**, is encouraged.

10.3 Accreditation or participation in recognised social enterprise, disability, or sustainability certification bodies is preferred.

Clause 11: Monitoring and Review

11.1 This Policy shall be reviewed annually by the Social Value Officer, with oversight by the Governance and Ethics Committee.

11.2 Performance will be reported to public sector commissioners upon request and included in tender feedback cycles.

Clause 12: Training and Awareness

12.1 All staff involved in procurement, contract management, or bid development must receive training on social value law and delivery.

12.2 Refresher training will be provided at least every two years, with updates following legislative changes or NHS policy amendments.

12.3 Staff participation and impact awareness will be tracked through training logs and reviewed during internal audits.

Clause 13: Digital Inclusion and Data Ethics

13.1 The Company will ensure equitable access to digital healthcare, assistive technology, and online services, particularly for digitally excluded groups.

13.2 All digital solutions shall be compliant with **Web Content Accessibility Guidelines (WCAG 2.1)** and **UK GDPR**.

13.3 AI and data use in social value delivery shall follow ethical frameworks to avoid algorithmic bias and promote inclusive outcomes.

Clause 14: Social Innovation and Co-Production

14.1 The Company shall involve community users, patient groups, and local partners in designing and validating social value commitments.

14.2 Co-production processes will be built into service improvement plans, pilot programmes, and feedback cycles.

14.3 Evidence of user-led innovation and partnership-led outcomes shall be submitted as part of social value reporting.